PreprintCited by 897Epigenetics and DNA MethylationChromatin Remodeling and CancerGenomics and Chromatin Dynamics

The DOI matches its Crossref record; 64 of the 68 references it cites were found in a registry or an index.

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

Open access

Tan, Jing, Yang, Xiaojing, Zhuang, Li, Jiang, Xia, Chen, Wei, Lee, Puay Leng, Karuturi, R.K. Murthy, Tan, Patrick Boon Ooi, Liu, Edison T., Yu, Qiang·2007·Genes & Development

DOI 10.1101/gad.1524107PMC PMC1855231

Open this paper in CoChat — free account Open PDF

Abstract

Polycomb-repressive complex 2 (PRC2)-mediated histone methylation plays an important role in aberrant cancer gene silencing and is a potential target for cancer therapy. Here we show that S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A (DZNep) induces efficient apoptotic cell death in cancer cells but not in normal cells. We found that DZNep effectively depleted cellular levels of PRC2 components EZH2, SUZ12, and EED and inhibited associated histone H3 Lys 27 methylation (but not H3 Lys 9 methylation). By integrating RNA interference (RNAi), genome-wide expression analysis, and chromatin immunoprecipitation (ChIP) studies, we have identified a prominent set of genes selectively repressed by PRC2 in breast cancer that can be reactivated by DZNep. We further demonstrate that the preferential reactivation of a set of these genes by DZNep, including a novel apoptosis affector, FBXO32 , contributes to DZNep-induced apoptosis in breast cancer cells. Our results demonstrate the unique feature of DZNep as a novel chromatin remodeling compound and suggest that pharmacologic reversal of PRC2-mediated gene repression by DZNep may constitute a novel approach for cancer therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/gad.1524107

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1
Beisel, C., Imhof, A., Greene, J., Kremmer, E., & Sauer, F. (2002) · Nature · doi:10.1038/nature01126 · Cited by 310
Retracted
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Regulation of chromatin structure by site-specific histone H3 methyltransferases
Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z.-W., Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Allis, C. D., et al. (2000) · Nature · doi:10.1038/35020506 · Cited by 2,845 · cited 1×
“In contrast, histone H3 trimethylation at Lys 9 (H3-K9me3)—which is mediated by another histone MTase, Suv39h1 (Rea et al. 2000; Peters et al. 2001; Lehnertz et al. 2003)—was not affected by DZNep treatment.”
Background
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Polycomb complexes repress developmental regulators in murine embryonic stem cells
Boyer, L. A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L. A., Lee, T. I., Levine, S. S., Wernig, M., Tajonar, A., Ray, M. K., et al. (2006) · Nature · doi:10.1038/nature04733 · Cited by 2,568
The history of cancer epigenetics
Feinberg, A. P., & Tycko, B. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1279 · Cited by 2,404
Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells
Lee, T. I., Jenner, R. G., Boyer, L. A., Guenther, M. G., Levine, S. S., Kumar, R., Chevalier, B. S., Johnstone, S. E., Cole, M. F., Isono, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.043 · Cited by 2,296
The Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204

Show all 68 references

Sorted by citations

Items 101–200 of 897

EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity
Yan, J., Ng, S., Tay, J. L.-S., Lin, B., Koh, T. L., Tan, J. M.-L., Selvarajan, V., Liu, S.-C., Bi, C., Wang, S., et al. (2013) · Blood · doi:10.1182/blood-2012-08-450494 · Cited by 165
Self-citation
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis
Crea, F., Fornaro, L., Bocci, G., Sun, L., Farrar, W. L., Falcone, A., & Danesi, R. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9387-3 · Cited by 165
CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells
Yang, X., Karuturi, R. K. M., Sun, F., Aau, M., Yu, K., Shao, R., Miller, L. D., Tan, P. B. O., & Yu, Q. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005011 · Cited by 166
Self-citation
Suppression of EZH2 Prevents the Shift of Osteoporotic MSC Fate to Adipocyte and Enhances Bone Formation During Osteoporosis
Jing, H., Liao, L., An, Y., Su, X., Liu, S., Shuai, Y., Zhang, X., & Jin, Y. J. (2015) · Molecular Therapy · doi:10.1038/mt.2015.152 · Cited by 165
Differentiation therapy of acute myeloid leukemia: past, present and future
Petrie, K. R., Zelent, A., & Waxman, S. (2009) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283257aee · Cited by 161
c-Myc-Mediated Epigenetic Silencing of MicroRNA-101 Contributes to Dysregulation of Multiple Pathways in Hepatocellular Carcinoma
Wang, L., Zhang, X., Jia, L., Hu, S.-J., Zhao, J., Yang, J., Wen, W., Wang, Z., Wang, T., Zhao, J., et al. (2013) · Hepatology · doi:10.1002/hep.26720 · Cited by 163
Enhancing Tumor T Cell Infiltration to Enable Cancer Immunotherapy
Zhang, J., Endres, S., & Kobold, S. (2019) · Immunotherapy · doi:10.2217/imt-2018-0111 · Cited by 159
Epigenetic regulation of normal and malignant hematopoiesis
Rice, K. L., Hormaeche, I., & Licht, J. D. (2007) · Oncogene · doi:10.1038/sj.onc.1210755 · Cited by 161
Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer
Asangani, I. A., Ateeq, B., Cao, Q., Dodson, L. M., Pandhi, M. B., Kunju, L. P., Mehra, R., Lonigro, R. J., Siddiqui, J., Palanisamy, N., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.10.008 · Cited by 158
FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma
Sehgal, L., Mathur, R., Braun, F., Wise, J. F., Berkova, Z., Neelapu, S. S., Kwak, L. W., & Samaniego, F. (2014) · Leukemia · doi:10.1038/leu.2014.126 · Cited by 153
EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma
Behrens, C., Solis, L. M., Lin, H. Y., Yuan, P., Tang, X., Kadara, H. N., Riquelme, E. M., Galindo, H., Moran, C. A., Kalhor, N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3946 · Cited by 155
Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors
Neumann, O., Kesselmeier, M., Geffers, R., Pellegrino, R., Radlwimmer, B., Hoffmann, K., Ehemann, V., Schemmer, P., Schirmacher, P., Bermejo, J. L., et al. (2012) · Hepatology · doi:10.1002/hep.25870 · Cited by 152
EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation
Wang, L., Chen, C., Song, Z., Wang, H., Ye, M., Wang, D., Kang, W., Liu, H., & Qing, G. (2022) · Nature Communications · doi:10.1038/s41467-021-27609-6 · Cited by 151
EZH2, an epigenetic driver of prostate cancer
Yang, Y. A., & Yu, J. (2013) · Protein & Cell · doi:10.1007/s13238-013-2093-2 · Cited by 153
EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-β1 and is a predictor of outcome in ovarian carcinoma patients
Rao, Z.-Y., Cai, M.-Y., Yang, G.-F., He, L.-R., Mai, S., Hua, W., Liao, Y.-J., Deng, H.-X., Chen, Y., Guan, X., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq150 · Cited by 152
Identification of Driver and Passenger DNA Methylation in Cancer by Epigenomic Analysis
Kalari, S. K., & Pfeifer, G. P. (2010) · Advances in genetics · doi:10.1016/b978-0-12-380866-0.60010-1 · Cited by 143
Chromatin and the DNA damage response: The cancer connection
Luijsterburg, M. S., & van Attikum, H. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.06.001 · Cited by 148
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
Wagener, N., Macher‐Goeppinger, S., Pritsch, M., Hüsing, J., Hoppe‐Seyler, K., Schirmacher, P., Pfitzenmaier, J., Haferkamp, A., Hoppe‐Seyler, F., & Hohenfellner, M. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-524 · Cited by 147
Oncogenic AURKA-enhanced N6-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells
Peng, F., Xu, J., Cui, B., Liang, Q., Zeng, S., He, B., Zou, H., Li, M., Zhao, H., Meng, Y., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00397-2 · Cited by 144
Diverse involvement of EZH2 in cancer epigenetics.
Völkel, P., Dupret, B., Bourhis, X. L., & Angrand, P. (2015) · PubMed · Cited by 142
RETRACTED: The Bmi-1 polycomb protein antagonizes the (−)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival
Balasubramanian, S., Adhikary, G., & Eckert, R. L. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp314 · Cited by 139
Retracted
Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2
Tsang, D. P., & Cheng, A. S. L. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06447.x · Cited by 141
Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells
Alimova, I. N., Birks, D. K., Harris, P. S., Knipstein, J. A., Venkataraman, S., Márquez, V. E., Foreman, N. K., & Vibhakar, R. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos285 · Cited by 142
Epigenetics in breast cancer: what's new?
Huang, Y., Nayak, S. R., Jankowitz, R. C., Davidson, N. E., & Oesterreich, S. (2011) · Breast Cancer Research · doi:10.1186/bcr2925 · Cited by 144
Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma
Asangani, I. A., Harms, P. W., Dodson, L. M., Pandhi, M. B., Kunju, L. P., Maher, C. A., Fullen, D. R., Johnson, T. M., Giordano, T. J., Palanisamy, N., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.622 · Cited by 135
Identification of a novel, recurrent MBTD1‐CXorf67 fusion in low‐grade endometrial stromal sarcoma
Dewaele, B., Przybył, J., Quattrone, A., Ferreiro, J. F., Vanspauwen, V., Geerdens, E., Gianfelici, V., Kalender, Z., Woźniak, A., Moerman, P., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28440 · Cited by 140
The Impact of One Carbon Metabolism on Histone Methylation
Serefidou, M., Venkatasubramani, A. V., & Imhof, A. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00764 · Cited by 131
Dual Targeting of Histone Methyltransferase G9a and DNA‐Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma
Bárcena‐Varela, M., Caruso, S., Llerena, S., Álvarez‐Sola, G., Uriarte, I., Latasa, M. U., Urtasun, R., Rebouissou, S., Alvarez, L., Jimenez, M., et al. (2019) · Hepatology · doi:10.1002/hep.30168 · Cited by 130
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
Pietersen, A. M., Horlings, H. M., Hauptmann, M., Langerød, A., Ajouaou, A., Cornelissen‐Steijger, P., Wessels, L. F. A., Jonkers, J., van de Vijver, M. J., & van Lohuizen, M. (2008) · Breast Cancer Research · doi:10.1186/bcr2214 · Cited by 127
Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells
Dimri, M., Bommi, P. V., Sahasrabuddhe, A. A., Khandekar, J. D., & Dimri, G. P. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp305 · Cited by 133
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis
Jiang, Y., Xiang, C., Zhong, F., Zhang, Y., Wang, L., Zhao, Y., Wang, J., Ding, C., Li, J., He, F., et al. (2020) · Theranostics · doi:10.7150/thno.46360 · Cited by 124
Epigenetic Histone Modification of Epstein-Barr Virus BZLF1 Promoter during Latency and Reactivation in Raji Cells
Murata, T., Kondo, Y., Sugimoto, A., Kawashima, D., Saito, S., Isomura, H., Kanda, T., & Tsurumi, T. (2012) · Journal of Virology · doi:10.1128/jvi.06768-11 · Cited by 127
(-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells
Choudhury, S. R., Balasubramanian, S., Chew, Y. C., Han, B., Márquez, V. E., & Eckert, R. L. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr171 · Cited by 124
Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment?
Khan, S. A. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i4.333 · Cited by 123
Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells
Hua, W., Fu, Y.-S., Liao, Y.-J., Xia, W.-J., Chen, Y., Zeng, Y.-X., Kung, H., & Xie, D. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.03.051 · Cited by 119
Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus
Tzao, C., Tung, H., Jin, J., Sun, G.-H., Hsu, H., Chen, B.-H., Yu, C., & Lee, S.-C. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.172 · Cited by 121
A complex Polycomb issue: the two faces of EZH2 in cancerPreprint
Hock, H. R. (2012) · Genes & Development · doi:10.1101/gad.191163.112 · Cited by 124
Epigenetic mechanisms of breast cancer: an update of the current knowledge
Karslı-Çeppioğlu, S., Dagdemir, A., Judes, G., Ngollo, M., Penault-Llorca, F. M., Pajon, A., Bignon, Y., & Bernard-Gallon, D. J. (2014) · Epigenomics · doi:10.2217/epi.14.59 · Cited by 121
Six Years (2012–2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2‐Pyridone Compounds
Fioravanti, R., Stazi, G., Zwergel, C., Valente, S., & Mai, A. (2018) · The Chemical Record · doi:10.1002/tcr.201800091 · Cited by 121
Roles of lncRNA in breast cancer
Watabe, K. (2015) · Frontiers in Bioscience-Scholar · doi:10.2741/s427 · Cited by 119
Down-Regulation of miR-101 in Endothelial Cells Promotes Blood Vessel Formation through Reduced Repression of EZH2
Smits, M., Mir, S. E., Nilsson, R. J. A., van der Stoop, P. M., Niers, J. M., Marquez, V. E., Cloos, J., Breakefield, X. O., Krichevsky, A. M., Noske, D. P., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016282 · Cited by 118
A histone demethylase is necessary for regeneration in zebrafish
Stewart, S., Tsun, Z.-Y., & Belmonte, J. C. I. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904132106 · Cited by 127
Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells
Kikuchi, J., Takashina, T., Kinoshita, I., Kikuchi, E., Shimizu, Y., Sakakibara‐Konishi, J., Oizumi, S., Márquez, V. E., Nishimura, M., & Dosaka‐Akita, H. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.08.003 · Cited by 118
Epigenetics and cancer
Kanwal, R., & Gupta, S. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00066.2010 · Cited by 124
Promoter hypermethylation of FBXO32, a novel TGF-β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer
Chou, J., Su, H., Chen, L., Liao, Y., Hartman-Frey, C., Lai, Y.-H., Yang, H., Deatherage, D. E., Kuo, C., Huang, Y., et al. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2009.138 · Cited by 119
The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling
Okada, T., Sinha, S., Esposito, I., Schiavon, G., López-Lago, M. A., Su, W., Pratilas, C. A., Abele, C., Hernandez, J. M., Ohara, M., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3082 · Cited by 117
Chromatin Regulator PRC2 Is a Key Regulator of Epigenetic Plasticity in Glioblastoma
Natsume, A., Ito, M., Katsushima, K., Ohka, F., Hatanaka, A., Shinjo, K., Sato, S., Takahashi, S., Ishikawa, Y., Takeuchi, I., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0109 · Cited by 123
Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression
Wu, Z., Zheng, S., Li, Z. M., Qiao, Y., Aau, M. Y., & Yu, Q. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.162 · Cited by 122
Self-citation
Emerging Epigenetic Targets and Therapies in Cancer Medicine
Popovic, R., & Licht, J. D. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0076 · Cited by 119
TXNIP (VDUP-1, TBP-2): A major redox regulator commonly suppressed in cancer by epigenetic mechanisms
Zhou, J., Yu, Q., & Chng, W. J. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.09.005 · Cited by 115
Self-citation
S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition
Hayden, A. L., Johnson, P., Packham, G., & Crabb, S. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0982-0 · Cited by 114
Epigenetic Regulation of Endothelial Lineage Committed Genes in Pro-Angiogenic Hematopoietic and Endothelial Progenitor Cells
Ohtani, K., Vlachojannis, G. J., Koyanagi, M., Boeckel, J., Urbich, C., Farcas, R., Bonig, H. B., Márquez, V. E., Zeiher, A. M., & Dimmeler, S. (2011) · Circulation Research · doi:10.1161/circresaha.111.247304 · Cited by 115
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
Puppe, J., Drost, R., Liu, X., Joosse, S. A., Evers, B., Cornelissen‐Steijger, P., Nederlof, P. M., Yu, Q., Jonkers, J., van Lohuizen, M., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2354 · Cited by 117
Self-citation
3‐Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor‐initiating hepatocellular carcinoma cells
Chiba, T., Suzuki, E., Negishi, M., Saraya, A., Miyagi, S., Konuma, T., Tanaka, S., Tada, M., Kanai, F., Imazeki, F., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26264 · Cited by 114
Downregulation of long noncoding RNA MEG3 is associated with poor prognosis and promoter hypermethylation in cervical cancer
Zhang, J., Lin, Z., Gao, Y., & Yao, T. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0472-2 · Cited by 115
Demethylation of H3K27 Is Essential for the Induction of Direct Cardiac Reprogramming by miR Combo
Dal-Pra, S., Hodgkinson, C. P., Mirotsou, M., Kirste, I., & Dzau, V. J. (2017) · Circulation Research · doi:10.1161/circresaha.116.308741 · Cited by 113
Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer
Yomtoubian, S., Lee, S. B., Verma, A., Izzo, F., Markowitz, G. J., Choi, H., Cerchietti, L. C. A., Vahdat, L. T., Brown, K. A., Andreopoulou, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.056 · Cited by 116
Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications
Wang, W. T., Qin, J., Voruganti, S., Nag, S. A., Zhou, J., & Zhang, R. (2015) · Medicinal Research Reviews · doi:10.1002/med.21358 · Cited by 118
Inhibition of Histone Lysine Methylation Enhances Cancer–Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer
Rao, M., Chinnasamy, N., Hong, J. A., Zhang, Y., Zhang, M. F., Xi, S., Liu, F., Márquez, V. E., Morgan, R. A., & Schrump, D. S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2442 · Cited by 113
Cancer epigenetics: above and beyond
Brait, M., & Sidransky, D. (2011) · Toxicology Mechanisms and Methods · doi:10.3109/15376516.2011.562671 · Cited by 115
Balancing histone methylation activities in psychiatric disorders
Peter, C. J., & Akbarian, S. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.02.003 · Cited by 111
Targeting the histone orthography of cancer: drugs for writers, erasers and readers
Simó‐Riudalbas, L., & Esteller, M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12844 · Cited by 111
Altered Histone Modifications in Gliomas
Kim, Y. Z. (2014) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2014.2.1.7 · Cited by 116
Activation of the Enhancer of Zeste Homologue 2 Gene by the Human Papillomavirus E7 Oncoprotein
Holland, D., Hoppe‐Seyler, K., Schuller, B., Lohrey, C., Maroldt, J., Dürst, M., & Hoppe‐Seyler, F. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1134 · Cited by 110
Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer
Taniguchi, H., Jacinto, F. V., Villanueva, A., Fernández, A. F., Yamamoto, H., Carmona, F. J., Puertas, S., Márquez, V. E., Shinomura, Y., Imai, K., et al. (2011) · Oncogene · doi:10.1038/onc.2011.387 · Cited by 110
Epigenetic Changes in the Myelodysplastic Syndrome
Issa, J. J. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.007 · Cited by 110
EZH2: Not EZHY (Easy) to Deal
Deb, G., Singh, A. K., & Gupta, S. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0546 · Cited by 110
Epigenomics of leukemia: from mechanisms to therapeutic applications
Florean, C., Schnekenburger, M., Grandjenette, C., Dicato, M. A., & Diederich, M. F. (2011) · Epigenomics · doi:10.2217/epi.11.73 · Cited by 107
Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets
Lawlor, E. R., & Thiele, C. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1921 · Cited by 104
Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy
Sasaki, D., Imaizumi, Y., Hasegawa, H., Osaka, A., Tsukasaki, K., Choi, Y. L., Mano, H., Márquez, V. E., Hayashi, T., Yanagihara, K., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.028605 · Cited by 104
Emerging EZH2 Inhibitors and Their Application in Lymphoma
Lue, J. K., & Amengual, J. E. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0466-6 · Cited by 106
Epigenetic downregulation of human disabled homolog 2 switches TGF-β from a tumor suppressor to a tumor promoter
Hannigan, A., Smith, P., Kalna, G., Lo Nigro, C., Orange, C., O’Brien, D. I., Shah, R., Syed, N., Spender, L. C., Herrera, B., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci36125 · Cited by 92
Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Kemp, C. D., Rao, M., Xi, S., Inchauste, S. M., Mani, H., Fetsch, P. A., Filie, A. C., Zhang, M. F., Hong, J. A., Walker, R. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0962 · Cited by 101
Environmental epigenetics in zebrafish
Cavalieri, V., & Spinelli, G. (2017) · Epigenetics & Chromatin · doi:10.1186/s13072-017-0154-0 · Cited by 105
A covalently bound inhibitor triggers EZH2 degradation through CHIP‐mediated ubiquitination
Wang, X., Cao, W., Zhang, J., Yan, M., Xu, Q., Wu, X., Wan, L., Zhang, Z., Zhang, C., Qin, X., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201694058 · Cited by 100
Self-citation
The noncanonical role of EZH2 in cancer
Huang, J., Gou, H., Yao, J., Yi, K., Jin, Z., Matsuoka, M., & Zhao, T. (2021) · Cancer Science · doi:10.1111/cas.14840 · Cited by 102
Orchestration of H3K27 methylation: mechanisms and therapeutic implication
Pan, M., Hsu, M., Chen, L., & Hung, W. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2596-8 · Cited by 111
Transcriptional regulation of cellular senescence
Lanigan, F., Geraghty, J. G., & Bracken, A. P. (2011) · Oncogene · doi:10.1038/onc.2011.34 · Cited by 95
Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer
Zhang, L., Deng, L., Chen, F., Yao, Y., Wu, B., Wei, L., Mo, Q., & Song, Y. (2014) · Oncotarget · doi:10.18632/oncotarget.2496 · Cited by 96
EZH2 Depletion Blocks the Proliferation of Colon Cancer Cells
Fussbroich, B., Wagener, N., Macher‐Goeppinger, S., Benner, A., Fälth, M., Sültmann, H., Holzer, A., Hoppe‐Seyler, K., & Hoppe‐Seyler, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021651 · Cited by 100
EZH2-Mediated Inactivation of IFN-γ-JAK-STAT1 Signaling Is an Effective Therapeutic Target in MYC-Driven Prostate Cancer
Wee, Z. N., Li, Z., Lee, P. L., Lee, S. T., Lim, Y. P., & Yu, Q. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.045 · Cited by 101
Self-citation
Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
Avan, A., Crea, F., Paolicchi, E., Funel, N., Galvani, E., Márquez, V. E., Honeywell, R. J., Danesi, R., Peters, G. J., & Giovannetti, E. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0037 · Cited by 102
A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep
Li, Y., Ren, Y., Wang, Y., Tan, Y., Wang, Q., Cai, J., Zhou, J., Yang, C., Zhao, K., Yi, K., et al. (2019) · Theranostics · doi:10.7150/thno.35188 · Cited by 101
EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
Li, B., & Chng, W. J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0814-6 · Cited by 101
Integrative pan cancer analysis reveals epigenomic variation in cancer type and cell specific chromatin domains
Gopi, L. K., & Kidder, B. L. (2021) · Nature Communications · doi:10.1038/s41467-021-21707-1 · Cited by 101
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells
Fiskus, W. C., Buckley, K., Rao, R., Mandawat, A., Yang, Y., Joshi, R., Wang, Y., Balusu, R., Chen, J., Koul, S., et al. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.10.8213 · Cited by 97
Enhancer of Zeste Homolog 2 Inhibition Stimulates Bone Formation and Mitigates Bone Loss Caused by Ovariectomy in Skeletally Mature Mice
Dudakovic, A., Camilleri, E. T., Riester, S. M., Paradise, C. R., Gluscevic, M., O'Toole, T. M., Thaler, R., Evans, J. M., Yan, H., Subramaniam, M., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.740571 · Cited by 97
Epigenome-Based Personalized Medicine in human Cancer
Yan, W., Herman, J. G., & Guo, M. (2015) · Epigenomics · doi:10.2217/epi.15.84 · Cited by 98
A TARBP2-Dependent miRNA Expression Profile Underlies Cancer Stem Cell Properties and Provides Candidate Therapeutic Reagents in Ewing Sarcoma
Vito, C. D., Riggi, N., Buros, S. C., Suvà, M.-L., Baumer, K., Provero, P., & Stamenkovic, I. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.023 · Cited by 96
EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway.
Chien, Y., Liu, L., Ye, H.-Y., Wu, J., & Yu, Y. (2018) · PubMed Central · Cited by 94
The Histone Methyltransferase Enzyme Enhancer of Zeste Homolog 2 Protects against Podocyte Oxidative Stress and Renal Injury in Diabetes
Siddiqi, F. S., Majumder, S., Thai, K., Abdalla, M., Hu, P., Advani, S. L., White, K., Bowskill, B. B., Guarna, G., dos Santos, C. C., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014090898 · Cited by 98
FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation
Zhou, H., Liu, Y., Zhu, R., Ding, F., Wan, Y., Li, Y., & Liu, Z. (2017) · Oncogene · doi:10.1038/onc.2016.479 · Cited by 98
Off-target effect of the BMI1 inhibitor PTC596 drives epithelial-mesenchymal transition in glioblastoma multiforme
Flamier, A., Abdouh, M., Hamam, R., Barabino, A., Patel, N., Gao, A. Y. L., Hanna, R., & Bernier, G. (2020) · npj Precision Oncology · doi:10.1038/s41698-019-0106-1 · Cited by 94
IGFBP-3 Is a Metastasis Suppression Gene in Prostate Cancer
Mehta, H. H., Gao, Q., Galet, C., Paharkova, V., Wan, J., SAID, J. W., Sohn, J. J., Lawson, G. W., Cohen, P., Cobb, L. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4513 · Cited by 94
Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance
Kikuchi, J., Kinoshita, I., Shimizu, Y., Kikuchi, E., Konishi, J. S., Oizumi, S., Kaga, K., Matsuno, Y., Nishimura, M., & Dosaka‐Akita, H. (2010) · Cancer · doi:10.1002/cncr.25128 · Cited by 94
TNFα-dependent hepatic steatosis and liver degeneration caused by mutation of zebrafishs-adenosylhomocysteine hydrolase
Matthews, R. P., Lorent, K., Mayoral, R., Huang, Y., Gong, W., Murray, I. V. J., Blair, I. A., & Pack, M. A. (2009) · Development · doi:10.1242/dev.027565 · Cited by 98
A chemical probe toolbox for dissecting the cancer epigenome
Shortt, J., Ott, C. J., Johnstone, R. W., & Bradner, J. E. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.148 · Cited by 94
Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage
Wu, Z., Lee, S. T., Qiao, Y., Li, Z., Lee, P. L., Lee, Y. J., Jiang, X., Tan, J. Y., Aau, M., Lim, C. Z. H., et al. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.48 · Cited by 95
Self-citation
Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition
Malouf, G. G., Taube, J. H., Lu, Y., Roysarkar, T., Panjarian, S. B., Estecio, M. R., Jelı́nek, J., Yamazaki, J., Raynal, N. J. ‐., Long, H., et al. (2013) · Genome biology · doi:10.1186/gb-2013-14-12-r144 · Cited by 98

Authors: Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q.
Affiliations: Genome Institute of Singapore (SG)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Duke-NUS Medical School (SG)
ORCID: Tan, Jing
Yang, Xiaojing
Zhuang, Li
Jiang, Xia
Chen, Wei
Lee, Puay Leng
Karuturi, R.K. Murthy
Liu, Edison T.
Yu, Qiang
Venue: Genes & Development
Publisher: Cold Spring Harbor Laboratory
Published: 2007-04-16
Volume: 21
Issue: 9
Pages: 1050-1063
ISSN: 0890-9369 (ISSN-L)
1549-5477
DOI: 10.1101/gad.1524107
PMC: PMC1855231
OpenAlex: W2113634596
Cited by: 895
References: 68
Citations by year: 2026: 12 · 2025: 16 · 2024: 18 · 2023: 35 · 2022: 21 · 2021: 35 · 2020: 39 · 2019: 37 · 2018: 44 · 2017: 65 · 2016: 55 · 2015: 65 · 2014: 98 · 2013: 77 · 2012: 70
Type: posted content
Language: en
Open access: bronze
doi.org
Locations: Genes & Development (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
National University of Singapore (submittedVersion)
Funders: Agency for Science, Technology and Research
National Cancer Institute
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords: polycomb repressive complex 2, DZNep, EZH2, SUZ12, EED, histone H3 lysine 27 methylation, gene silencing, apoptosis, breast cancer, atrogin-1, chromatin remodeling, cancer therapy
MeSH terms: Adenosine, Base Sequence, Breast Neoplasms, Enzyme Inhibitors, Female, Histones, Humans, Methylation, Promoter Regions, Genetic, Repressor Proteins, RNA Polymerase II, Apoptosis, RNA Interference, RNA, Small Interfering, Chromatin Assembly and Disassembly, Adenosylhomocysteinase, Epigenesis, Genetic, Cell Line, Tumor, Chromatin Immunoprecipitation, Polycomb-Group Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks